News

On February 14, 2025, the FDA approved the first rapid-acting biosimilar insulin product called nsulin-aspart-szjj (Merilog).

Children with severe atopic dermatitis saw > 5 percentile height gains after 16 weeks of dupilumab, per a study to be presented at AAAAI 2025.

In this quiz, we test your knowledge of anaphylaxis risk assessment, prevention strategies, and best practices for enhancing preparedness.

In patients with HCV-related compensated cirrhosis, DAA treatment was linked to lower HCC risk than no treatment but similar risk to a historical IFN cohort.

Around half of participants had insufficient vitamin D levels.

Cardiovascular clinical outcome trials require a large number of sites to meet enrollment targets, but patient-per-site ratios were often low.

In this retrospective analysis, orally administered tofacitinib was shown to be efficacious among younger patients with alopecia areata due to regrowth results.

A Kingston study finds a 15.94% biphasic anaphylaxis rate, with recurrence at 19 hours, prompting concerns about extending emergency department observation.

Lee explains study findings suggesting MetALD classification should be based on ≥ 3 cardiometabolic risk factors rather than just alcohol intake.

This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.

These data highlight a variety of comorbidities linked to dermatologic diseases in children with obesity, including common comorbidities such as asthma.

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well as patients’ unmet needs.

The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.

A study found higher daily temperatures increased anaphylaxis risk, except for cases related to medical procedures, highlighting heat's role in allergic reactions.

Higher Dietary Inflammatory Index scores were associated with an increased risk of developing chronic liver disease and cirrhosis progression.

In the final segments of this 4-part episode, the discussion focuses on the use of HCEs in different kidney disease trials.

In part 3 of 4 from this episode, the discussion focuses on potential limitations to HCEs and addressing skepticism around their use in nephrology.

In part 2 of 4 from this episode, the discussion focuses on hierarchical composite endpoints and their use in nephrology trials and research.

In part 1 of 4 from this episode, the discussion focuses on traditional composite endpoints in nephrology trials and the use of HCEs.

Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.

These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.

Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.